Key facts
- It has raised $259.0M; the latest was Early Stage VC ($30.0M) in Apr 2026.
- Notable investors include Lenovo Capital and Incubator Group, Guolian Investment, GSR United Capital, Beijing Delian Yuntong Investment Management Company, Oceanpine Capital — 13 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 13 names
- ·Watchlist + deal alerts for Rigerna
- ·The full record, as it builds
Funding rounds
No funding rounds for Rigerna are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Rigerna
Manufacturer of innovative nucleic acid therapeutics intended to advance treatment for liver and non-liver diseases. The company offers proprietary drug delivery platforms, core nucleic acid technology, and expertise in chemistry, biology, and clinical development, enabling pharmaceutical companies and patients to access highly targeted, effective, and next-generation nucleic acid medicines.
- Sector
- Healthcare
- HQ
- Suzhou, China
- Founded
- 2022
- Website
- rigerna.com/
- Ownership
- Privately Held (backing)
Rigerna doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Rigerna shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Rigerna in its N-PORT filings yet. We sweep new filings monthly.